IL5 and Alzheimer disease: In summary, a single exposure to TSLP/SEB is sufficient to drive immune hallmarks of AD, including type 2 chemokine biomarkers and pathogenic effector type 2 T cells secreting high IL-13 and IL-5 from healthy PBMCs, validated here to correlate with AD activity in adult patients with the moderate-to-severe disease [48].